MYC and neoplasm: SOCS3 silencing has been reported to increase the expression of c-Myc and tumorigenesis [42], and accordingly, its expression has been found to be lower in breast, ovarian, and colon cancers [43] and glioblastoma [44] in comparison with tumor-adjacent tissues.